YGEN.L Regulatory News (YGEN)

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Further testing service agreement for MyHealthChecked plc

Yourgene Genomic Services to support MHC's second Boots agreement for Day 2 & Day 8 testing

 for international arrivals to the UK

Manchester, UK - 17 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its partner MyHealthChecked plc (AIM:MHC) ("MyHealthChecked") has signed a second COVID-19 testing services agreement, to support the supply of the MyHealthChecked™ COVID-19 at-home nasal swab kit, PCR laboratory testing service and logistics for day two and day eight ("D2/D8") coronavirus testing for international arrivals, to Boots UK Limited ("Boots"), the health and beauty retailer and pharmacy group.

Through the service agreement, a proportion of the MyHealthChecked™ COVID-19 tests will be processed by Yourgene Genomic Services ("YGS") at the Company's Citylabs 1.0 laboratory in Manchester which are well equipped to deal with the anticipated increased demand for D2/D8 testing. In addition, samples processed at MyHealthChecked's own laboratories will use Yourgene's Clarigene® SARS CoV-2 PCR CE-IVD test kit. MyHealthChecked is currently the only at-home testing kit provider within Boots for General Testing and Fit-to-Fly services, as launched on 7 April 2021, and is now accompanied by D2/D8 tests that will be available to purchase online, via www.boots.com across the UK, from 17 May 2021.

Lyn Rees, CEO of Yourgene Health and Non-Executive Director of MyHealthChecked, commented: "This further contract with Boots is another significant milestone for MyHealthChecked and Yourgene is pleased to continue supporting their COVID-19 testing service and product supply to their laboratory. With the introduction of the new traffic light system in the UK for global travel, we will see an increased demand for D2/D8 testing, as travel resumes, and this further contract for MyHealthChecked is a testament to the quality of the service provided."

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.